Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

» Details

Guru Trades

XPH Guru Trades in

XPH Guru Trades in

XPH Guru Trades in

Q4 2014

XPH Guru Trades in Q4 2014

Ken Fisher 3,425 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with XPH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
EV-to-EBIT 27.80
XPH's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 27.80 )
XPH' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 27.8

PEG 1.20
XPH's PEG is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 1.20 )
XPH' s 10-Year PEG Range
Min: 0   Max: 1.2
Current: 1.2

0
1.2

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.60
XPH's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 1.60 )
XPH' s 10-Year Dividend Yield Range
Min: 0   Max: 0
Current: 1.6

Yield on cost (5-Year) 1.60
XPH's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 1.60 )
XPH' s 10-Year Yield on cost (5-Year) Range
Min: 0   Max: 0
Current: 1.6

Valuation & Return

vs
industry
vs
history

Business Description

Industry: »
Compare:KH, CTFO, GBG, URGP, GPRM » details
» More Articles for XPH

Headlines

Articles On GuruFocus.com
No related article found.

More From Our Partners
A Beginner's Guide to Pharma ETFs - ETF News And Commentary Apr 17 2015 - ZACKS

More From Other Websites
The Zacks Analyst Blog Highlights: Powershares Dynamic Pharmaceuticals ETF, SPDR S&P Pharmaceuticals... Apr 20 2015
A Beginner's Guide to Pharma ETFs - ETF News And Commentary Apr 17 2015
Pharma ETFs Soar on Acquisition Spree - ETF News And Commentary Apr 13 2015
Healthcare ETFs Rally on Monday Merger Mania - ETF News And Commentary Mar 31 2015
Prowling Teva Could Boost Some Pharma ETFs Mar 30 2015
No Surprise: Healthcare ETFs See Rapid Asset Growth Mar 19 2015
Salix Bidding War Provides Modest Boost for Pharma ETFs Mar 11 2015
Big pharma diversifies business to mitigate patent risk Feb 24 2015
Pharma ETFs in Focus on Valeant-Salix Deal - ETF News And Commentary Feb 24 2015
These ETFs Might Enjoy the Salix Takeover News Feb 23 2015
Wednesday Market Recap Feb 11 2015
SPDR® ETF Family Announces Impact of Receiving Settlement Payment Feb 10 2015
McAleer on Cutting Healthcare ETF Allocation (Audio) Jan 07 2015
The Zacks Analyst Blog Highlights: Actavis, Allergan, iShares U.S. Pharmaceuticals ETF, Market... Nov 19 2014
Pharma ETFs in Focus on Allergan Takeover Deal Nov 18 2014
Guru ETFs Turn Gimpy as Stocks Slide Oct 16 2014
Zacks Investment Ideas feature highlights: WisdomTree Japan Hedged Equity Fund, Europe Hedged Equity... Sep 23 2014
Best ETF Strategies for the Fourth Quarter Sep 22 2014
[video] Alzheimer drug controversy Sep 17 2014
Is Akorn, Inc. An Easy Buy This Week? Sep 16 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK